Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06671977 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
A Phase 1 study of Depression and Major Depression Disorder, sponsored by Deepak C. D'Souza.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06671977 is a Phase 1 study of Depression and Major Depression Disorder that is actively recruiting participants, run by Deepak C. D'Souza. The registered enrollment target is 60 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06671977, a Phase 1 study of Depression and Major Depression Disorder, is actively recruiting participants, sponsored by Deepak C. D'Souza.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this phase 1 study is to investigate the safety and efficacy of dimethyltryptamine (DMT) in individuals with depression and healthy controls. We hypothesize that administration of DMT will result in decreases in depression, associated symptoms, and neuroplastic changes in depressed subjects. We expect that DMT will induce changes in neuroplasticity as indexed using electroencephalographic (EEG) measures and tasks in both depressed individuals and healthy volunteers, though to different degrees. These neuronal changes may in parallel cause changes in mood measured both in healthy and depressed subjects, which will be captured using appropriate psychometric measures of mood.
Conditions Studied
Interventions
- DRUG DMT-Medium Dose
- DRUG DMT-Low Dose
- DRUG THC-Medium Dose
- DRUG THC-Low Dose
Study Locations (1)
Connecticut
- Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-03-14 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06671977
The ClinicalTrials.gov registry entry for NCT06671977 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (92% lower). The listed sponsor is Deepak C. D'Souza, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 4 interventions - of which DMT-Medium Dose is the first listed.
NCT06671977 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT06671977 about?
NCT06671977 is a clinical study titled "Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans". The goal of this phase 1 study is to investigate the safety and efficacy of dimethyltryptamine (DMT) in individuals with depression and healthy controls. We hypothesize that administration of DMT will result in decreases in depression, associated symptoms, and neuroplastic changes in depressed subje...
What is the current status of trial NCT06671977?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-03-14. Estimated completion is 2027-12-01.
What conditions does trial NCT06671977 study?
This clinical trial studies the following conditions: Depression, Major Depression Disorder.
What interventions are being tested in trial NCT06671977?
The interventions under investigation include: DMT-Medium Dose (DRUG), DMT-Low Dose (DRUG), THC-Medium Dose (DRUG), THC-Low Dose (DRUG).
Who is sponsoring clinical trial NCT06671977?
This trial is sponsored by Deepak C. D'Souza, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06671977 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 1
-
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
RECRUITING · Phase 1
-
[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET
RECRUITING · Phase 1
-
Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department
RECRUITING · Phase 1
-
A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.